A cardiologist or an electrophysiologist  should recommend what each patient should do.

1) A patient who only has an occasional epsisode of atrial fibrillation  may be able to take the pill in the pocket approach. For example they could take Flecainide tablets when atrial fibrillation occurs and take Pradaxa capsules  for a short time to prevent clot formation.
2) A patient who has frequent episodes may have to take medication all the time to prevent atrial fibrillation and take one of the newer anticoagulants all the time. The most commonly used anti-arrhythmic drugs are flecainide, amiodarone, propafenone, disopyramide and dronedarone.

3) Left atrial appendage closure

Attached to the top left chamber of the heart (the left atrium) is a "pocket" which is called the left atrial appendage. Although blood clots in the heart can sometimes form in the top chambers of the heart (the atria), in 9 out of 10 cases they occur in this "pocket" (the left atrial appendage). It is possible to close or block the entrance between the top left chamber of the heart and this pocket (the left atrial appendage), by using a special device called a left atrial appendage closure device. This device is fitted during an operation. Some devices are fitted inside the pocket, and involve special thin flexible tubes (electrodes) being passed into your heart through a blood vessel, usually in your groin or neck, and then the device is inserted into your heart through these tubes. Other devices are fitted on the outside of this pocket during a surgical procedure.

Not every patient is suitable for a left atrial appendage closure device. This device is not usually considered as the first treatment option to try to reduce the risk of stroke in patients with atrial fibrillation. The main treatment option for reducing the risk of stroke in the majority of people with atrial fibrillation is a blood-thinning medicine (an anticoagulant). The left atrial appendage closure device may be an alternative treatment option if you are not able to take any of the blood-thinning medicines, usually because of a very high risk of bleeding. Several different left atrial appendage closure devices are available and your doctor will discuss the available options if this type of device is a suitable treatment option for you.

You will need to take aspirin or a blood-thinning medicine for at least 6 weeks after having this device fitted. Aspirin can increase the risk of serious bleeding. In addition, only 9 out of 10 blood clots are formed in the left atrial appendage (pocket) and therefore having this device fitted does not completely remove the risk of stroke. Depending on your risk of stroke you may need to continue taking a blood-thinning medicine after you have had the device fitted.

The left atrial appendage in the left atrium is one of the areas in which blood is more likely to pool during atrial fibrillation, which can lead to the development of a blood clot. Several new procedures make it possible to close off blood flow to and from this part of the heart. A special device can be inserted using a catheter placed in the left atrium, then the catheter is removed and  the device is left in place in the left atrial appendage. Other devices are applied to the outside of the left atrial appendage during surgical procedures.

Not every patient is suitable for a left atrial appendage closure device.  These devices arenot usually considered as the first treatment option to try to reduce the risk of stroke in patients with atrial fibrillation.  The main treatment option for reducing the risk of stroke in the majority of people with atrial fibrillation is a blood-thinning medicine (an anticoagulant).  The left atrial appendage closure device may be an alternative treatment option if you are not able to take any of the blood-thinning medicines, usually because of a very high risk of bleeding.  http://www.afibmatters.org/Treatments

4) Catheter Ablation

Boehringer Ingelheim announced that the FDA has granted Breakthrough Therapy designation to idarucizumab, an investigational fully humanized antibody fragment (Fab), being evaluated as a specific antidote for Pradaxa (dabigatran etexilate mesylate).

Data from a Phase 1 trial demonstrated that idarucizumab was able to achieve immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy humans. The on-set of action of the antidote was detected immediately following a 5-minute infusion while thrombin time was reversed with idarucizumab. Reversal of the anticoagulation effect was complete and sustained in 7 of 9 subjects who received the 2g dose and in 8 out of 8 subjects who received the 4g dose. The 1g dose resulted in complete reversal of anticoagulation effect; however, after approximately 30 minutes there was some return of the anticoagulation effects of dabigatran.

The cardiologist I consulted said aspirin was a ' weak option '. He also said fish oil wouldn't prevent a stroke in someone who has atrial fibrillation.